Whitehawk Therapeutics (NASDAQ:WHWK) CEO Sells $322,718.41 in Stock

Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) CEO David James Lennon sold 94,087 shares of the business’s stock in a transaction on Tuesday, April 7th. The stock was sold at an average price of $3.43, for a total transaction of $322,718.41. Following the sale, the chief executive officer owned 597,067 shares in the company, valued at $2,047,939.81. The trade was a 13.61% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

David James Lennon also recently made the following trade(s):

• On Wednesday, April 8th, David James Lennon sold 63,945 shares of Whitehawk Therapeutics stock. The stock was sold at an average price of $3.40, for a total value of $217,413.00.
• On Monday, April 6th, David James Lennon sold 102,395 shares of Whitehawk Therapeutics stock. The stock was sold at an average price of $3.51, for a total transaction of $359,406.45.
• On Thursday, April 2nd, David James Lennon sold 26,858 shares of Whitehawk Therapeutics stock. The stock was sold at an average price of $3.48, for a total transaction of $93,465.84.
• On Monday, March 2nd, David James Lennon sold 5,100 shares of Whitehawk Therapeutics stock. The stock was sold at an average price of $3.31, for a total transaction of $16,881.00.

Whitehawk Therapeutics Stock Down 0.6%

Shares of Whitehawk Therapeutics stock traded down $0.02 on Wednesday, hitting $3.41. The company’s stock had a trading volume of 212,634 shares, compared to its average volume of 201,638. Whitehawk Therapeutics, Inc. has a 52-week low of $1.39 and a 52-week high of $4.48. The firm has a fifty day moving average price of $3.32 and a 200-day moving average price of $2.69. The company has a market capitalization of $160.95 million, a P/E ratio of 7.26 and a beta of 0.57.

Whitehawk Therapeutics (NASDAQ:WHWK) last released its quarterly earnings data on Thursday, March 12th. The company reported ($0.34) EPS for the quarter, topping the consensus estimate of ($0.55) by $0.21.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Avoro Capital Advisors LLC acquired a new position in Whitehawk Therapeutics in the 3rd quarter valued at about $5,414,000. Suvretta Capital Management LLC acquired a new position in Whitehawk Therapeutics in the 3rd quarter valued at about $7,030,000. Ally Bridge Group NY LLC acquired a new position in Whitehawk Therapeutics in the 3rd quarter valued at about $1,554,000. Peapod Lane Capital LLC acquired a new position in Whitehawk Therapeutics in the 3rd quarter valued at about $577,000. Finally, ABG Innovation Capital Partners III GP Ltd acquired a new position in Whitehawk Therapeutics in the 3rd quarter valued at about $51,000. Institutional investors and hedge funds own 52.08% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the stock. Wall Street Zen upgraded shares of Whitehawk Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, March 21st. Oppenheimer started coverage on shares of Whitehawk Therapeutics in a research report on Thursday, February 5th. They issued an “outperform” rating and a $6.00 price objective on the stock. JonesTrading started coverage on shares of Whitehawk Therapeutics in a research note on Monday, December 22nd. They issued a “buy” rating and a $7.00 target price for the company. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Whitehawk Therapeutics in a research note on Friday, March 27th. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $6.50.

About Whitehawk Therapeutics

Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.